Peer-reviewed veterinary case report
Benazepril and pimobendan combo tested in dogs with heart failure
By King, Jonathan N et al.·Published in Journal of veterinary science·2018·Elanco Animal Health·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of a fixed-dose combination of benazepril and pimobendan in dogs with congestive heart failure: a randomized non-inferiority clinical trial.
- Species:
- dog
Plain-English summary
A group of dogs with congestive heart failure (CHF) caused by a heart valve problem were treated with a new combination tablet called Fortekor Plus, which contains benazepril and pimobendan. The dogs receiving Fortekor Plus had similar improvements in their heart condition compared to those taking the individual medications, but they experienced significantly less vomiting. This means that Fortekor Plus is just as effective as the separate treatments and is easier on the stomach. Overall, the dogs showed better heart health without the added side effect of vomiting.
People also search for: dog congestive heart failure treatment · Fortekor Plus for dogs · pimobendan side effects in dogs
Abstract
A fixed-dose combination tablet of benazepril and pimobendan (Fortekor Plus; Elanco Animal Health) was tested in dogs with congestive heart failure (CHF) caused by myxomatous mitral valve disease (MMVD) in a three-arm, masked, randomized, non-inferiority clinical trial in Japan. The test group (n = 34) received Fortekor Plus twice daily. Two control groups received registered formulations of benazepril (Fortekor; Elanco Animal Health) and pimobendan (Vetmedin; Boehringer Ingelheim Vetmedica) with administration of Vetmedin twice daily and Fortekor twice (Control I, n = 14) or once (Control II, n = 19) daily. Diuretics were used in 22 dogs (32.8%). Global clinical scores decreased significantly from baseline in all groups; there were no significant differences between groups, and non-inferiority of Fortekor Plus compared to Control I, Control II, and combined Control I + II groups was demonstrated. There were no significant differences between groups for relevant clinical chemistry and hematology variables or frequency of all adverse events. Frequency of emesis was significantly (= 0.0042) lower in the Fortekor Plus (8.8%) group than in the Control I + II (39.4%) group. In conclusion, Fortekor Plus had non-inferior efficacy and was associated with significantly less emesis compared to Fortekor and Vetmedin in dogs with CHF caused by MMVD.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/28693297/